Pre-made Fianlimab benchmark antibody ( Whole mAb, anti-LAG3 therapeutic antibody, Anti-CD223 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-210

Pre-Made Fianlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fianlimab (previously REGN 3767) is an anti-lymphocyte-activation gene 3 (LAG3) monoclonal antibody, being developed by Regeneron Pharmaceuticals, for the treatment of solid tumours and haematological malignancies.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-210-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Fianlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody
INN Name Fianlimab
TargetLAG3
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions ActiveCancer
Conditions Discontinuedna
Development Techna